Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Timeline

Start

2011-06

Primary completion

2012-03

Completion

2012-03

Outcome

Met primary endpoint

registry PF-04991532 450 mg vs Placebo; p = 0.0017; LS Mean Difference -0.49 (80% CI -0.71 to -0.28) NCT01336738 ↗

Drugs

Indications